MSD to Acquire Ophthalmology Specialist Eyebiotech in a Deal Valued Up to USD 3 Billion
Merck, Sharp & Dohme (MSD; NYSE: MRK) has entered into an agreement to acquire UK-based...
FDA Extends Indication for BMS’ CAR-T Therapy Breyanzi to Include Relapsed MCL in Adults
The US Food and Drug Administration (FDA) has granted Bristol Myers Squibb (BMS; NYSE: BMY)...
Novartis Halts Development of KRAS Inhibitor Opnurasib Due to Competitive Market
Swiss pharmaceutical giant Novartis AG (NYSE: NVS) has reportedly halted the development of its Phase...
Eli Lilly Launches New Formula of Taltz in China with Reduced Injection Site Pain
Eli Lilly and Company (NYSE: LLY), a leading pharmaceutical company in the U.S., has announced...
TÜV Partners with Lancy Co., Ltd’s BRAVOU to Enhance Medical Aesthetics Services in China
Technischer Überwachungs-Verein (TÜV), a Germany-based international independent third-party testing, inspection, and certification organization, has entered...
Burning Rock Expands Companion Diagnostics Partnership with Bayer for Precision Oncology in China
Burning Rock Ltd (NASDAQ: BNR), a China-based medical technology company, has announced another partnership in...
Parexel Partners with Ruijin Hospital Hainan Subsidiary to Enhance Real-World Evidence in Drug Development
Parexel, a U.S.-based contract research organization (CRO), has entered into a partnership with Shanghai Ruijin...
Hengrui Pharmaceuticals Advances Two Drug Candidates Following NMPA Clinical Trial Green Lights
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...
JW Therapeutics Presents Positive Clinical Data for Carteyva in SLE at EULAR 2024
JW Therapeutics (HKG: 2126), a biopharmaceutical company based in China, has presented new clinical data...
Akeso Inc.’s Ivonescimab Shows Positive Interim Analysis in Phase III NSCLC Study
Akeso Inc. (HKG: 9926), a biopharmaceutical company based in China, has announced positive interim analysis...
Lucy Therapeutics Boosts CNS Disease Research with USD 12.5 Million in Additional Financing
Lucy Therapeutics Inc., a U.S.-based developer of small-molecule drugs for central nervous system (CNS) diseases,...
Laekna Therapeutics Initiates Phase III Trial for Breast Cancer Candidate LAE002 in Combination with Fulvestrant
Laekna Therapeutics Shanghai Co., Ltd, a biopharmaceutical company based in China, has announced the enrollment...
Merck KGaA Launches Construction on Largest Asia-Pacific Investment with South Korean Bioprocessing Plant
Merck KGaA (ETR: MRK), the German science and technology company, has commenced construction on a...
Shanghai Research Team Achieves Global First in Treating Type 2 Diabetes with Stem Cell Therapy
A groundbreaking study out of Shanghai has made a significant stride in diabetes treatment. A...
Johnson & Johnson to Acquire Atopic Dermatitis Therapy NM26 in $1.25 Billion Deal
Johnson & Johnson (J&J; NYSE: JNJ), a global healthcare giant, has entered into a definitive...
Jiangsu QYuns Therapeutics Initiates Phase III Trial for Skin Disease Candidate QX005N
Jiangsu QYuns Therapeutics Co., Ltd (HKG: 2509), a biopharmaceutical company based in China, has announced...
HuidaGene and Synthego Form Strategic Partnership for CRISPR-Based Therapies
HuidaGene (Shanghai) Biotechnology Co., Ltd, a clinical-stage biotechnology company based in China, has entered into...
Wanbangde’s Huperzine A Earns Orphan Drug Status from FDA for Treating Neonatal Brain Injury
Wanbangde New Building Materials Co., Ltd (SHE: 002082), a company operating in China, has announced...
Zelgen Biopharmaceuticals Gets NMPA Approval for Jacktinib Vitiligo Trial in Adolescents and Adults
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a biopharmaceutical company based in China, has received...
Hengrui Pharmaceuticals’ Vitiligo Treatment SHR0302 and Diabetes Drug HRS9531 Get Green Light from China’s NMPA
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading biopharmaceutical company based in China, has...